The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan, North America, and Europe. Shionogi is headquartered in Osaka, Japan.Shionogi & Co Ltd Key Recent Developments
- Sep 25, 2025: Shionogi Highlights Japan’s Role in Global Health with Bill Gates - Discussing Fight Against Infectious Diseases and Future of Healthcare Models under Theme “Japan’s Role in Advancing Global Health”:
- Aug 29, 2025: Shionogi Selected for METI’s FY2024 Supplementary Grant Program for Co-Creation with Global South - Study on Digital Solutions to Appropriate Use of Japan Antimicrobials and Hygiene Products in Kenyan
- Aug 04, 2025: Shionogi to Exhibit at the 9th Tokyo International Conference on African Development (TICAD9) and Participate in a Stage Event
- Jul 28, 2025: Shionogi : Consolidated Financial Results for the First Quarter of Fiscal Year 2025 (IFRS)
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Wakamoto Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- Santen Pharmaceutical Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Chugai Pharmaceutical Co Ltd

